We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, ...

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

As Loren Shook prepares to hand over the reins of the memory care company he helped build as a model for the industry, his one wish is that the company’s vision to innovate and bring quality of life ...

Researchers have discovered a promising new drug combination that significantly lowers “bad” LDL cholesterol for people whose ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

Q1 2025 Management View CEO David Mazzo emphasized the company’s continued momentum despite market challenges, highlighting significant progress in advancing the clinical development of its lead ...

Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q ...